{
    "nct_id": "NCT03372057",
    "official_title": "A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",
    "inclusion_criteria": "1. Age â‰¥ 18 years of age\n2. Diagnosis of one of the following histologic subtypes of PTCL, pathologically confirmed, as defined by the World Health Organization:\n\n   1. Peripheral T-cell lymphoma-not otherwise specified;\n   2. Angioimmunoblastic T-cell lymphomas;\n   3. Anaplastic large cell lymphoma (ALCL); or\n   4. Natural-killer/T-cell lymphoma\n3. Received at least 2 cycles of one standard regimen for newly diagnosed advanced PTCL, and one of the following:\n\n   1. failed to achieve at least a PR after 2 or more cycles of standard therapy;\n   2. failed to achieve a CR after completion of standard therapy; and/or\n   3. persistent or progressive disease after an initial response\n4. For participants with CD30+ ALCL, failed or are ineligible or intolerant to brentuximab vedotin\n5. Measurable disease as defined by Lugano for PTCL, that is, at least 1 measurable disease lesion > 1.5 centimeters in at least one dimension by conventional techniques (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography [CT], CT with contrast, magnetic imaging resonance)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Primary leukemic PTCL subtypes (that is, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, adult T-cell leukemia/lymphoma and aggressive NK-cell leukemia) or transformed mycosis fungoides\n2. Received prior allogeneic transplant\n3. Received prior treatment with a PI3K inhibitor\n4. Known central nervous system involvement by PTCL\n5. Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids > 20 mg of prednisone (or equivalent) once daily\n6. Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening\n7. Known hypersensitivity to duvelisib and/or its excipients",
    "miscellaneous_criteria": ""
}